Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Myriad Genetics (MYGN) EBIT Margin: 2009-2025

Historic EBIT Margin for Myriad Genetics (MYGN) over the last 16 years, with Sep 2025 value amounting to -11.33%.

  • Myriad Genetics' EBIT Margin fell 195.00% to -11.33% in Q3 2025 from the same period last year, while for Sep 2025 it was -50.95%, marking a year-over-year decrease of 3689.00%. This contributed to the annual value of -14.74% for FY2024, which is 1943.00% up from last year.
  • As of Q3 2025, Myriad Genetics' EBIT Margin stood at -11.33%, which was up 92.67% from -154.48% recorded in Q2 2025.
  • Myriad Genetics' 5-year EBIT Margin high stood at -9.38% for Q3 2024, and its period low was -154.48% during Q2 2025.
  • Over the past 3 years, Myriad Genetics' median EBIT Margin value was -17.26% (recorded in 2024), while the average stood at -34.33%.
  • As far as peak fluctuations go, Myriad Genetics' EBIT Margin spiked by 6,230bps in 2021, and later plummeted by 13,722bps in 2025.
  • Quarterly analysis of 5 years shows Myriad Genetics' EBIT Margin stood at -26.80% in 2021, then plummeted by 256bps to -29.36% in 2022, then soared by 1,339bps to -15.97% in 2023, then slumped by 255bps to -18.52% in 2024, then slumped by 195bps to -11.33% in 2025.
  • Its EBIT Margin was -11.33% in Q3 2025, compared to -154.48% in Q2 2025 and -14.80% in Q1 2025.